SUSTAIN Trial Results — T2D Cardiovascular Safety

SUSTAIN Trial Results

Released: June 1, 2026Last reviewed: November 6, 2026

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

Clinical referencePubMed-linked

Researched By

Dr. Parmis

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Overview

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.